

227th Business Plan Presentations Held on May 11, 2021

TIME SHARING SHINYOKOHAMA-A

1. IDEAAI Corp. President Mr. Akihiro Ogura

http://ideaai.co.jp/hp/wp-content/themes/ideaai/index-top_en.php

Established in June 2019 Capital stock: USD \$ 17,100

By incorporating leading-edge image processing technology that takes account of the manufacturing process at the client company into AI learning, IDEAAI Corp. has achieved a number of detectable defects that is several times as large as those of competitors, as well as a detection rate on a par with that of veteran inspectors.

Last year, its system was introduced on the mass-production line of a major Taiwanese manufacturer of electronic components (Taiwan JMC), and has been very effective

Going forward, the company has in mind business development targeting the production lines of electronic component manufacturers.

【Re-Cap】 The company's name, which is pronounced "idea AI," is a coinage combining "idea" in the Platonic sense of pure form, truth, or archetype and the abbreviation for "artificial intelligence." The yearly market for image recognition solutions applying AI in Japan now comes to an estimated 150 billion yen. IDEAAI is aiming for the transmission (digitization) of the know-how of seasoned engineers and reduction of errors through AI utilization. The detection subjects in cases of application of its technology include road signs and traffic signals, intrusion of obstacles onto railroads, and road abnormalities.



2. Physiologas Technologies Inc. President Mr. Kazuyoshi Miyawaki

<https://physiologas.co.jp/>

Established in March 2020 Capital stock: USD \$ 65,000

Physiologas Technologies Inc. is engaged in the development of compact hemodialysis equipment especially for use in the home. It began hiring employees this April and has commenced full-fledged development activities. It plans to develop a core technology implementation method and design the overall equipment this year, with a view to launching product sales in 2025.

【Re-Cap】 Hemodialysis machines use large amounts of water and purify the blood of patients whose main kidney function (urination) has been eliminated by kidney failure. At present, dialysis patients have to go to a hospital for treatment three times a week. Mr. Miyawaki said that the ability to have treatment in the home would free them from various constraints and also improve their condition. The company's ultimate goal is the delivery of dialysis care that is friendly to the patient, based on the development of compact hemodialysis machines that apply all sorts of newly developed technology and are geared for treatment in the home.



3. S&K Biopharma, Inc. President Mr. Shinji Kagaya

<https://skagayasandk.wixsite.com/website>(Japanese)

Established in April 2020 Capital stock: USD \$ 115,000 (including reserve funds)

S&K Biopharma has discovered a new molecular target for lactoferrin, a highly safe glycoprotein, and is developing lactoferrin drugs for use as therapeutics for corresponding diseases. In addition, in response to the poor stability of lactoferrin within blood, it successfully developed two types of lactoferrin fusion protein, which is prepared by fusion with an IgG-Fc domain or human serum albumin.

As for the first disease targeted in this work, the company plans to develop a lactoferrin fusion protein to treat rapidly progressive glomerulonephritis, a designated intractable disease. The mechanism of action is lactoferrin's effect for inhibiting excessive formation of neutrophil extracellular traps (NETs). For the second and succeeding target diseases, it intends to develop a therapeutic for spinal cord injuries whose action mechanism is lactoferrin's neutralizing effect on chondroitin sulfate, and gradually expand the scope of its application.

【Re-Cap】 When they hear the word "lactoferrin," people think of the ingredient in milk and yogurt, for example. Its specific effects cover a wide range, including anti-aging benefits and allergies. Mr. Kagaya said that S&K Biopharma has the aspiration of helping its products grow into therapeutics that top Humira (whose sales came to about 19.8 billion dollars in 2020). Because lactoferrin is a biological preparation, the development entails a huge expense, and the company is looking for partners for joint research.



《Impressions》

This month's meeting attracted the participation of many people by both online means and actual attendance at the venue. At this last meeting, too, there were presentations by companies in diverse fields. Each was cultivating new markets, and it will be interesting to see how their business develops from now on. If your company would like to make a presentation at the meeting, please contact us at an early date, because the schedule is filled up for a few months in advance.